MGMansi Gupta

Mansi Gupta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mansi Gupta has a total of 132 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Prevalence of Relapse in Pulmonary Sarcoidosis: A Systematic Review

    by Zia Hashim, Robert Baughman, Ritesh Agarwal, Naresh Kumar Tripathy, Mansi Gupta, Ajmal Khan, Ajit Kumar Jha, Anup Kumar, Alok Nath

    Background and objectiveRelapse after treatment discontinuation or reduction frequently occurs in pulmonary sarcoidosis (PS), but reported rates vary widely. We conducted a systematic review and meta-analysis to estimate relapse prevalence and evaluate risk factors.MethodsWe searched PubMed, Embase, Scopus, and Google Scholar from inception through January 2026 for studies reporting relapse prevalence in PS. Two reviewers independently extracted data on relapse prevalence, timing, definitions, and predictors, and assessed study quality using the Hoy et al. tool. We calculated pooled prevalence using random effects models, assessed heterogeneity using I2, and performed subgroup analyses and meta-regression.ResultsWe included 51 studies comprising 6076 patients; 3682 were followed up, and 1442 relapsed. Pooled relapse prevalence was 0.39 (95% CI, 0.33-0.45) with substantial heterogeneity (I2=94%). Relapse prevalence was lower in prospective (0.31, 95% CI: 0.25-0.37) than retrospective (0.45, 95% CI: 0.36-0.54) studies. Only 23 (45%) studies provided explicit relapse definitions, which varied across clinical, radiological, functional, and biomarker criteria. Advanced radiographic stage was associated with higher relapse odds than stage I (log OR 0.55-1.04, p<0.05), and Black race with higher odds than White race (log OR 0.91, p<0.01). Relapse prevalence did not differ between clinical-only versus composite definitions.ConclusionsApproximately two-fifths of PS patients relapse after treatment reduction or discontinuation. Marked heterogeneity in relapse definitions and observational study designs underscores the need for standardized criteria. Clinical assessment appears comparable to complex definitions for assessing relapse.

  • Development and validation of the Hypersensitivity Pneumonitis South Asian Questionnaire for Exposure (HP-SAQE): a novel, qualitative and quantitative tool

    by Sheetu Singh, Ambika Sharma, Khushboo Pilania, Prerna Singh, Arvind Kumar Sharma, Sahajal Dhooria, Vijay Hadda, Nitesh Gupta, Mansi Gupta, Amila Rathnapala, et al.

    Introduction There is an unmet need for a validated qualitative and quantitative tool to assess environmental exposures in patients with interstitial lung disease (ILD). This study aimed to develop and validate a comprehensive tool to systematically identify exposures in patients with ILD. Methods A systematic literature search was completed to identify exposures associated with more than five documented hypersensitivity pneumonitis (HP) cases. These exposures were evaluated through a two-round Delphi survey involving 39 pulmonologists from India, Sri Lanka, Pakistan and Nepal. The questionnaire was prospectively derived at one centre and validated across five centres in India and Sri Lanka. The HP South Asian Questionnaire for Exposure (HP-SAQE) was validated against the gold standard multidisciplinary discussion diagnosis, distinguishing HP from non-HP ILD. Results The literature search screened 5170 records and included 407 studies, identifying 24 exposures. A 50-item Delphi survey achieved expert consensus (>70%) on 17 qualitative and 4 quantitative items (six questions) by 39 pulmonologists. HP-SAQE score ranged from 0 to 14. After pilot testing, the questionnaire was translated into Hindi, Tamil and Sinhala. In the derivation cohort (n=40), the HP-SAQE score was significantly higher in patients with HP versus non-HP (mean: 10.2±1.6 vs 6.7±4.2; p=0.001). This finding was validated in a separate cohort (n=163; mean: 9.4±2.2 vs 4.13±4.28; pConclusion The HP-SAQE is the first qualitative and quantitative exposure assessment tool for patients with ILD that has a good diagnostic performance.


  • Open Access

    Isolated pulmonary artery choriocarcinoma masquerading as pulmonary embolism diagnosed by endovascular biopsy: A case report and systematic review

    by Krishanu Mukhoti, Mansi Gupta, Manish Ora, Neha Nigam, Tanya Yadav, R Baskaran, Alok Nath

    Choriocarcinoma is an aggressive malignant trophoblastic tumour of rare occurrence, which often presents with multiple metastases, including lungs, brain, liver, kidneys, and lymph nodes. However, primary choriocarcinoma of the pulmonary artery is an even rarer and highly malignant clinical entity that is difficult to diagnose and treat timely. Less than 15 cases have been reported so far in the literature. In this case report, a 38-year-old female presented with recurrent pulmonary thromboemboli despite being on adequate anticoagulation. Positron emission tomography/computed tomography (PET/CT) showed an abnormally hypermetabolic uptake in the pulmonary artery thrombi, suggesting tumour emboli. Catheter-guided aspiration thrombectomy followed by pathological examination confirmed non-gestational choriocarcinoma originating from the pulmonary arteries. The patient underwent treatment under a medical oncologist and responded well to the treatment. A literature search revealed only 12 reported cases. Diagnosis of primary pulmonary artery choriocarcinoma requires a high index of suspicion. Suspicion rises manifold when a reproductive age group female presents with recurrent pulmonary thromboembolism with raised serum βhCG levels.


  • Open Access

    Relationship of fractional exhaled nitric oxide with blood eosinophilia in characterizing type-2 airway inflammation in treatment-naïve patients with chronic obstructive pulmonary disease

    by Riksoam Chatterjee, Mansi Gupta, Zia Hashim, Ajmal Khan, Alok Nath, Vikas Aggarwal

    Fractional exhaled nitric oxide (FeNO), a sensitive and reproducible, non-invasive biomarker for type-2 (T2) inflammation in asthma, remains underutilized in chronic obstructive pulmonary disease (COPD). We investigated the potential role of FeNO and its relationship with blood eosinophilia in characterizing T2 airway inflammation in COPD. A single-center prospective observational study was conducted in 75 treatment-naïve adult patients with stable COPD and 75 age-sex-matched controls. The Global Initiative for Chronic Obstructive Lung Disease criteria were used for the diagnosis of COPD. FeNO levels were compared with clinico-radiological features, pulmonary functions, and other markers of T2 inflammation in COPD. Participants in the COPD subgroup had a median age of 62 (55.0, 69.0) years with a male predominance (77.3%). The median FeNO value was 27.0 ppb (19.0, 39.0) in COPD and 14.0 ppb (10.0, 20.0) in controls (p<0.001). FeNO values were categorized as low (≤25 ppb), intermediate (25-50 ppb), and high (≥50 ppb), with 57.3% of COPD patients having intermediate to high FeNO. In contrast, 46.7% of these patients had an absolute eosinophil count (AEC) ≥300/mm³. Higher values of FeNO in COPD were associated with the history of atopy (p<0.001), a positive bronchodilator reversibility on spirometry (p<0.05), and high-resolution computed tomography findings such as emphysema, bronchial wall thickening, bronchiectasis/bronchiolectasis, and mosaic attenuation (p<0.05). In addition, FeNO levels showed a strong positive linear correlation with serum immunoglobulin E (IgE) levels (r²=0.66, p<0.001) and AEC (r²=0.56, p<0.001). FeNO's best diagnostic cut-off level to detect T2 inflammation was 31 ppb (sensitivity: 65.9%, specificity: 86.5%; area under the receiver operating characteristic curve: 0.79). FeNO measurement, besides blood eosinophilia, is an effective, direct, airway-specific, non-invasive tool for detecting T2 airway inflammation in stable patients with COPD. Atopy (IgE sensitization) is a crucial factor in explaining higher FeNO values in COPD patients. FeNO correlates well with blood eosinophilia in COPD patients with an eosinophilic phenotype as a surrogate biomarker with good sensitivity and specificity.

  • Open Access

    Rare cause of chronic cough in a young healthcare worker - A case of exogenous lipoid pneumonia!

    by Nandini Dikshit, Mansi Gupta, Neha Nigam, Alok Nath

    A BSTRACT: Exogenous lipoid pneumonia (ELP) is a rarely reported entity caused by aspirating or inhaling fat or oil-containing substances. Clinically, patients present with subacute to chronic-onset non-specific symptoms such as cough, fever, breathlessness, and general malaise. In addition, lobar or multifocal interstitial and parenchymal infiltrates on chest imaging can mimic any other infectious etiology. Diagnosis of lipoid pneumonia is often missed or delayed in many cases and requires a high index of clinical suspicion. We report a case of a 36-year-old nursing officer who presented with a cough and right-sided pneumonia on chest imaging. She was being treated empirically with antitubercular therapy without any clinical response to the treatment. ELP was diagnosed after carefully evaluating the radiological findings, reviewing the clinical history, and finding supportive evidence of lipid-laden alveolar macrophages in her broncho-alveolar lavage fluid. It is vital to uphold a heightened clinical suspicion for non-infectious etiologies in non-resolving pneumonia and investigate the patient thoroughly before resorting to empirical treatments.


  • Open Access

    Guidelines for Antibiotics Prescription in Critically Ill Patients

    by Dhruva Chaudhry, Mukesh Desai, Mansi Gupta, Anant Mohan, Yatin Mehta, Manju Sengar, Deepak Govil, Ashit Hegde, Narendra Rungta, Saurabh Mittal, et al.

    How to cite this article: Khilnani GC, Tiwari P, Mittal S, Kulkarni AP, Chaudhry D, Zirpe KG, et al. Guidelines for Antibiotics Prescription in Critically Ill Patients. Indian J Crit Care Med 2024;28(S2):S104-S216.


  • Open Access

    BOOKSTORE ON CLOUD

    by Priya, Mansi Gupta, Sarvadnya, A Tarkar, Riddhesh, R Rajwadkar, Tushar, Prabhakar Mishra, Shrivastav Rohit

  • Open Access

    Effect of glucocorticoids on the development of COVID-19-associated pulmonary aspergillosis: a meta-analysis of 21 studies and 5174 patients

    by Zia Hashim, Alok Nath, Ajmal Khan, Mansi Gupta, Anup Kumar, Riksoam Chatterjee, Radha Krishan Dhiman, Martin Hoenigl, Naresh Kumar Tripathy

    Objective: COVID-19-associated pulmonary aspergillosis (CAPA) remains a high mortality mycotic infection throughout the pandemic, and glucocorticoids (GCs) may be its root cause. We aimed to evaluate the effect of systemic GC treatment on the development of CAPA. Methods: We systematically searched the PubMed, Google Scholar, Scopus, and Embase databases to collect eligible studies published until December 31, 2022. The pooled outcome of CAPA development was calculated as the log odds ratio (LOR) with 95% confidence intervals (CI) using a random effect model. Results: A total of 21 studies with 5174 patients were included. Of these, 20 studies with 4675 patients consisting of 2565 treated with GC but without other immunomodulators (GC group) and 2110 treated without GC and other immunomodulators (controls) were analyzed. The pooled LOR of CAPA development was higher for the GC group than for the control group (0.54; 95% CI: 0.22, 0.86; p<0.01). In the subgroups, the pooled LOR was higher for high-dose GC (0.90; 95% CI: 0.17, 1.62: p=0.01) and dexamethasone (0.71; 95% CI: 0.35, 1.07; p<0.01)-treated patients, but there was no significant difference for low-dose GC (0.41; 95% CI: -0.07, 0.89; p=0.09)- and non-dexamethasone GC (0.21; 95% CI: -0.36, 0.79; p=0.47)-treated patients versus controls. Conclusion: GC treatment increased the risk of CAPA development, and the risk was associated with the use of high-dose GC or dexamethasone therapy.

  • MAREMADS: Microgravity and radiation effects on musculoskeletal atrophy detection system

    by Tuhin Sengupta, Huda Altaf, Mansi Gupta, Ashok Kumar Devaraj, Varshini Karthik

    Exploring the space and its extremities is still in its infancy. An astronaut is exposed to an un- pleasant bounty of multiple complications coupled with physiological and psychological ill effects. This paper deals with analyzing various ill effects on human body caused due to muscular exoskeleton atrophy and its future assessment based on duration of stay in space for planning space missions. In this paper, OpenSim, free software has been used to study bio mechanics effects on the body. Gravity settings have been changed using MATLAB. Simulated values of pre and post flight parameters have been compared to analyze the adverse effect on human body. The objective was to calculate and show how the radiation and microgravity play a major cause for the cause of muscle atrophy in astronauts. The effects were recorded in simulated software by comparing data at earth and zero gravity scenario. This study can be extremely useful to analyze and predict the amount of expected muscle atrophy in astronauts for a specific space mission. It will also facilitate in ascertaining and implementing required preventive measures in all manned space missions to be launched in the future.